Nasdaq · Healthcare
CRISPR Therapeutics AG (CRSP)
As-reported financials and recent SEC filings for CRISPR Therapeutics AG, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.5M
Net income
$-581.6M
Net margin
—
Diluted EPS
$-6.47
ROE
-30.3%
P/E (TTM)
—
Market cap
$5.41B
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-664.6M | $-466.6M | $-222.5M | $-673.2M | $373.5M |
| Net income | $-581.6M | $-366.3M | $-153.6M | $-650.2M | $377.7M |
| Diluted EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →Go deeper on CRSP
Search CRISPR Therapeutics AG’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.